Danaher Corporation is a global science and technology company that designs, manufactures, and markets a diverse range of industrial and healthcare products and solutions. The company's operations are organized into several segments, including life sciences, diagnostics, dental, and environmental and applied solutions. Danaher focuses on advancing vital sciences and technologies through innovative products and services that enhance the quality of life. With a commitment to customer satisfaction, the company leverages its extensive expertise in engineering and manufacturing to deliver reliable and efficient solutions across various industries, helping to drive improved outcomes in healthcare, environmental monitoring, and industrial processes. Read More
New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government shutdown and a disappointing jobs report. As investors sought refuge in defensive plays and reacted to
New York, NY – October 1, 2025 – Shares of Danaher Corporation (NYSE: DHR) surged by a robust 6.6% today, following a significant announcement from its life sciences subsidiary, Leica Biosystems. The unveiling of an expanded suite of artificial intelligence (AI)-powered digital pathology solutions has sent a clear signal to
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent strategic developments. This significant uptick reflects investor confidence in the life sciences giant's aggressive expansion into high-growth sectors,
Shares of diversified science and technology company Danaher (NYSE:DHR)
jumped 6.6% in the afternoon session after its subsidiary, Leica Biosystems, announced the launch of new artificial intelligence (AI)-powered digital pathology solutions.
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Over the last six months, Danaher’s shares have sunk to $186.35, producing a disappointing 9.1% loss - a stark contrast to the S&P 500’s 18.6% gain. This may have investors wondering how to approach the situation.
In a week poised to redefine the landscape of advanced technology, the Technical University of Denmark (DTU) has unveiled two monumental advancements set to send ripples through the financial markets and technology sector. Just days before the current date of September 29, 2025, DTU-led research has demonstrated a groundbreaking quantum
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Danaher Corporation (NYSE: DHR).
In the current market session, Danaher Inc. (NYSE: DHR) price is at $183.36, after a 1.05% spike. However, over the past month, the stock fell by 10.91%, and in the past year, by 34.05%.
Danaher Corp (DHR) excels as a quality investment, showing strong revenue growth, a high 38.86% ROIC, solid financial health, and excellent cash flow conversion.
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
NEW YORK, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR).
NEW YORK and NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Danaher Corporation (NYSE: DHR).
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR).
In a development that has sent ripples of concern through financial markets, the U.S. Treasury yield curve underwent a significant un-inversion in April 2025, following its longest inversion in history, spanning from 2022 through 2024. This shift, characterized by short-term interest rates falling below long-term rates once again, initially
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Danaher (NYSE:DHR) and the rest of the research tools & consumables stocks fared in Q2.
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR).
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 1.4% gain for healthcare stocks has fallen short of the S&P 500’s 15.5% rise.
RBC Capital upgraded Bio-Techne, citing M&A confidence, margin gains, and growth potential after a sharp stock drop and alignment with sector valuations.
